Skip to main content
    A

    Akari Therapeutics PLC (AKTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.19
    -0.61 (-8.97%)

    Market Cap: $15.54M

    Last updated: Nov 17, 2026 at 10:59 AM ET

    Akari Therapeutics PLC (AKTX) Earnings: Report Dates and Results

    Updated Aug 13, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Akari Therapeutics (AKTX) is expected to report earnings on Mar 29, 2027. In the quarter ended Jun 30, 2026, Akari Therapeutics reported EPS of -$2.69, below the -$1.04 estimate. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    42%(8/19)
    Avg Surprise
    +3.26%

    Upcoming Estimates

    Reports Mar 29, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.94
    RangeN/A
    4 analysts
    Revenue Consensus
    N/A
    RangeN/A
    4 analysts
    Reports May 17, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$2.09
    Range-$2.09 - -$2.09
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.00n/a
    7d ago$0.00n/a
    Current-$2.09
    Revenue Consensus
    N/A
    RangeN/A
    0 analysts

    Next Report

    AKTX has an expected report date of Mar 29, 2027.

    Earnings History

    Of the 22 quarters below that had an estimate, AKTX beat 11, missed 8 and matched 3. The widest gap in the table came in the quarter ended Dec 31, 2019, when EPS landed 178.57% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Jun 30, 2026-$2.69-$1.04-$1.04 - -$1.04-158.47%MissN/A11 up, 0 downAug 13, 2026
    Mar 31, 2026-$9.72-$0.66N/AN/AN/AN/A10 up, 0 downApr 7, 2026
    Sep 30, 2025-$1.06-$4.40-$4.40 - -$4.40+75.91%BeatN/A10 up, 0 downNov 13, 2025
    Jun 30, 2025-$3.92-$4.80-$4.80 - -$4.80+18.33%BeatN/A10 up, 0 downAug 13, 2025
    Mar 31, 2025-$0.19-$1.00N/A+81.00%BeatN/AN/AN/AApr 14, 2025
    Sep 30, 2024-$9.59N/AN/AN/AN/AN/AN/AN/ANov 18, 2024
    Jun 30, 2024-$0.80N/AN/AN/AN/AN/AN/A0 up, 0 downAug 18, 2024
    Mar 31, 2024-$0.83N/AN/AN/AN/AN/AN/A0 up, 0 downMay 14, 2024
    Dec 31, 2023-$2.40N/AN/AN/AN/AN/AN/A0 up, 0 downMar 29, 2024
    Sep 30, 2023Not reported-$0.60N/AN/ANot reportedN/AN/A0 up, 0 downOct 3, 2023
    Jun 30, 2023Not reported-$40.00N/AN/ANot reportedN/A10 up, 0 downJul 19, 2023
    Mar 31, 2023-$0.08-$0.07N/A-14.29%MissN/AN/AN/AMay 1, 2023
    Dec 31, 2022-$0.08-$0.07N/A-14.29%MissN/AN/AN/AMar 9, 2023
    Sep 30, 2022-$0.04-$0.04N/A0.00%In lineN/AN/AN/ADec 30, 2022
    Jun 30, 2022-$0.10N/AN/AN/AN/AN/AN/AN/ASep 27, 2022
    Mar 31, 2022-$0.12N/AN/AN/AN/AN/AN/AN/AMay 16, 2022
    Sep 30, 2021-$0.03N/AN/AN/AN/A-172.1%N/A0 up, 0 downDec 3, 2021
    Jun 30, 2021-$0.15N/AN/AN/AN/AN/AN/A0 up, 0 downSep 22, 2021
    Mar 31, 2021-$0.01N/AN/AN/AN/AN/AN/AN/AApr 20, 2021
    Sep 30, 2020$0.04N/AN/AN/AN/AN/AN/AN/ADec 11, 2020
    Jun 30, 2020-$2.00N/AN/AN/AN/AN/AN/AN/ASep 1, 2020
    Mar 31, 2020-$0.13N/AN/AN/AN/AN/AN/AN/AMay 29, 2020
    Dec 31, 2019-$0.39-$0.14-$0.29 - $0.00-178.57%MissN/A2N/AMar 31, 2020
    Sep 30, 2019-$0.14-$0.12-$0.24 - $0.00-16.67%MissN/A2N/ANov 4, 2019
    Jun 30, 2019-$0.25-$0.13-$0.27 - $0.00-92.31%MissN/A2N/AAug 29, 2019
    Mar 31, 2019-$0.15-$40.00-$80.00 - $0.00+99.63%BeatN/A2N/AApr 23, 2019
    Dec 31, 2018-$0.22N/AN/AN/AN/AN/AN/AN/AMar 18, 2019
    Sep 30, 2018-$0.24-$8.00N/A+97.06%BeatN/AN/AN/ANov 15, 2018
    Jun 30, 2018-$0.53-$0.40-$0.58 - -$0.30-32.50%MissN/A2N/AAug 17, 2018
    Mar 31, 2018-$0.58-$0.72N/A+19.44%BeatN/A2N/AMay 30, 2018
    Dec 31, 2017-$8.00-$8.00N/A0.00%In lineN/A2N/AMar 21, 2018
    Sep 30, 2017-$8.00-$8.00N/A0.00%In lineN/A2N/ANov 13, 2017
    Jun 30, 2017-$0.03-$560.00N/A+100.00%BeatN/A2N/AAug 10, 2017
    Mar 31, 2017-$8.00-$432.00-$608.00 - -$432.00+98.15%BeatN/A3N/AMay 15, 2017
    Dec 31, 2016-$1.00-$0.83N/A-20.48%Miss-284.4%N/AN/AMar 31, 2017
    Sep 30, 2016-$0.04-$664.00N/A+99.99%BeatN/AN/AN/ANov 10, 2016
    Jun 30, 2016-$4.00-$808.00N/A+99.50%BeatN/AN/AN/AAug 11, 2016
    Mar 31, 2016-$0.30-$1.01N/A+70.30%BeatN/AN/AN/AMay 12, 2016
    Dec 31, 2015$0.54N/AN/AN/AN/AN/AN/AN/AMar 23, 2016
    Sep 30, 2015-$6.20N/AN/AN/AN/AN/AN/AN/ANov 23, 2015
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$16.47, after -$2.62 in the fiscal year ended Dec 31, 2022. It was -$478.85 for the year ended Dec 31, 2013, the oldest of the 8 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$16.47N/A
    Dec 31, 2022-$2.62N/A
    Dec 31, 2019-$0.93N/A
    Dec 31, 2018-$1.57N/A
    Dec 31, 2017-$24.03N/A
    Dec 31, 2016-$5.34N/A
    Dec 31, 2015-$12.51N/A
    Dec 31, 2013-$478.85N/A

    Frequently Asked Questions About AKTX

    When is Akari Therapeutics's next earnings date?

    Akari Therapeutics's next earnings report is expected for Mar 29, 2027.

    Did AKTX beat earnings estimates last quarter?

    No. Akari Therapeutics reported EPS of -$2.69 for the quarter ended Jun 30, 2026, below the -$1.04 estimate by 158.47%.

    What EPS do analysts expect from AKTX next quarter?

    The consensus EPS estimate for Akari Therapeutics for the quarter ending Dec 31, 2026 is -$0.94 from 4 analysts.

    How often does AKTX beat earnings estimates?

    Akari Therapeutics beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of -23.80%.